AstraZeneca (AZN) has released an update.
AstraZeneca has finalized a significant equity investment in Cellectis, a biotech firm specializing in gene editing, to co-develop up to 10 new cell and gene therapy products. This completion follows an initial payment of $105 million and an additional $140 million investment, resulting in AstraZeneca holding approximately 44% equity in Cellectis. The collaboration could lead to AstraZeneca receiving exclusive licensing rights for these products, with Cellectis eligible for further milestone payments and royalties.
For further insights into AZN stock, check out TipRanks’ Stock Analysis page.
